CAYRA KNOWLEDGE / HIV+ PATIENT GUIDES
Kidney transplant for HIV patients in Turkey is a transplant-centre decision, not a standard medical-tourism booking. Current international guidance supports equitable access for eligible people with HIV, while requiring stable HIV management, donor and legal review, interaction-safe immunosuppression and lifelong specialist follow-up.
Updated 20 August 2026 · Evidence-led patient information · Individual eligibility requires specialist review
PRIVATE, CASE-BY-CASE REVIEW
HIV status alone does not answer whether a procedure is appropriate. The treating specialist reviews the procedure, current health, HIV control, medicines and recovery plan together.
QUICK ANSWER
HIV is no longer an automatic barrier to kidney transplantation. NIH guidance recommends equitable access for eligible people with HIV and multidisciplinary care before, during and after transplant. Acceptance criteria, donor pathways and legal documentation vary by country and centre. This article does not confirm that Cayra currently provides or coordinates kidney transplantation; a named authorized transplant centre must first accept the patient and, where relevant, the donor.
| Review area | Why it matters | What may be requested |
|---|---|---|
| Kidney disease | The team must confirm transplant indication and urgency. | Nephrology summary, cause of kidney failure, eGFR trend, dialysis records, imaging and prior transplant/access operations. |
| HIV management | Stable treatment and an interaction-safe plan are central to transplant care. | ART history, recent viral load/CD4 information, resistance history and HIV clinician contact. |
| Infection and cancer screening | Immunosuppression can reactivate or worsen infections and affects malignancy risk. | TB, HBV/HCV, CMV/EBV and other centre-specific screening; vaccination and cancer-screening records. |
| Donor and continuity | Living-donor suitability and lifelong follow-up cannot be arranged as travel extras. | Donor relationship/identity documents, donor medical evaluation, legal/ethics review, funding and home transplant-team plan. |
The U.S. NIH antiretroviral guidelines state that people with HIV who are eligible for solid-organ transplantation should have equitable access. They recommend multidisciplinary care, maintenance of viral suppression, vaccination review and selection of ART that minimizes interactions. This is an important change from older exclusionary practice, but it is not automatic approval.
Each transplant programme has its own protocol. The team commonly evaluates current virologic control, immune and opportunistic-infection history, ART adherence and resistance, kidney diagnosis, cardiovascular status, cancer history, hepatitis coinfection, substance use where relevant, psychosocial support and the ability to follow a lifelong medicine and monitoring plan. A single CD4 result or “undetectable” status cannot replace this complete assessment.
Urgent dialysis problems require local nephrology care; international travel should not delay treatment of fluid overload, severe electrolyte disturbance, access infection or other emergencies. Transplant evaluation and immediate kidney-failure management are different workstreams.
After transplantation, medicines such as tacrolimus, cyclosporine, sirolimus or everolimus may have narrow therapeutic ranges. Some antiretrovirals strongly inhibit or induce drug-metabolizing pathways and can cause very large changes in immunosuppressant exposure. The NIH guideline therefore advises choosing or maintaining an ART regimen that minimizes interactions and performing therapeutic drug monitoring for transplant recipients.
Integrase-inhibitor-based ART without a pharmacokinetic booster is often easier to manage, but only the HIV and transplant specialists can select a regimen using the person’s resistance history, kidney function, HBV status and previous tolerance. Patients should never switch ART to fit a marketing package or stop it during travel.
Transplant immunosuppression increases susceptibility to infection. Screening is centre-specific and may include tuberculosis, hepatitis B and C, CMV, EBV, syphilis and other tests based on geography and history. Active infection usually needs treatment before an elective transplant. Previous opportunistic illness should be reviewed by transplant infectious-disease and HIV specialists.
The NIH transplant guidance recommends bringing vaccinations up to date. Timing matters because some live vaccines are not used after significant immunosuppression and immune response may be reduced. The transplant team—not a travel coordinator—should define the schedule. Cancer screening also needs to reflect age, sex, organs, HIV-associated risk and prior disease.
Dental infection, skin wounds and dialysis-access problems should be reported. Fever, chills, shortness of breath, confusion, chest pain, falling urine output or signs of access infection need urgent local medical attention rather than waiting for remote transplant advice.
Türkiye performs kidney transplantation and permits living kidney donation within its legal and ethical framework, according to Ministry of Health information. That general fact does not establish that a particular foreign patient or donor is eligible. Relationship documentation, independent donor evaluation, consent, ethics review, residency/nationality rules, payment rules and required records must be confirmed directly with the authorized transplant centre under current law.
The Ministry of Health publishes lists of healthcare providers authorized for international health tourism and a current international-health-tourism regulation. Transplantation also requires a specifically authorized transplant programme. Ask for the full hospital and transplant-centre identity, the transplant surgeon and nephrologist, and written confirmation that the centre has accepted both recipient and proposed donor for evaluation.
Do not book flights until a transplant centre has reviewed the records and explained whether the first visit is evaluation only. The recipient may need cardiology, infectious-disease, dental, urology, imaging, tissue typing and other work-up. A proposed living donor needs an independent medical and psychosocial assessment and may be declined even if willing.
After transplant, frequent blood tests and dose adjustments are expected, especially early. Rejection, infection, drug toxicity, wound problems and urinary complications can require urgent treatment. Before leaving Türkiye, the home transplant unit should accept the handover and receive the operation report, donor/recipient compatibility information, pathology where relevant, current immunosuppressant doses and levels, ART plan, infection prophylaxis, laboratory trend and emergency contacts.
Cayra’s current public service pages do not verify a kidney-transplant programme. The contact team may be asked whether a suitable authorized partner pathway can be identified, but patients should not interpret that enquiry as acceptance. Review Cayra’s general treatment coordination information and organizational profile separately from the transplant centre’s credentials.
Yes, eligible people with HIV should have equitable access to transplant. Acceptance remains centre-specific and depends on kidney disease, HIV control, infection and cancer review, surgical fitness, adherence and long-term follow-up.
No. Viral suppression is important, but programmes also assess immune and infection history, ART resistance, organ and cardiovascular health, cancer risk, psychosocial support and ability to manage lifelong medicines.
Yes. Some ART drugs can substantially change immunosuppressant concentrations. Transplant and HIV specialists should choose compatible regimens and perform close therapeutic drug monitoring.
Possibly, but eligibility and documentation are governed by current Turkish law and the authorized transplant centre’s donor and ethics process. The centre must independently evaluate and accept the donor; a facilitator cannot approve this.
Cayra’s current public pages reviewed for this article do not verify that capability. Ask for written confirmation of the named authorized transplant centre, team and accepted pathway before treating any coordination discussion as a service offer.
No fixed medical-tourism stay applies. Early monitoring is intensive, and travel depends on graft function, drug levels, infection and wound status, complications and formal handover to a home transplant team.
Continue your research with these verified live Cayra pages:
This guide is educational and does not replace advice from your HIV clinician or treating specialist.
If you request feasibility support, send a nephrology summary, dialysis records, HIV history, full medicine list and proposed donor information. No transplant pathway exists until an authorized centre accepts the evaluation.
No treatment, price, date or eligibility is confirmed until the appropriate specialist and facility have reviewed the case.